Published in final edited form as:

J Med Chem. 2010 August 12; 53(15): 5567–5575. doi:10.1021/jm1007165.

Substituted *E*-3-(3-indolylmethylene)1,3-dihydroindol-2-ones with Antitumor Activity. In-depth study of the effect on growth of breast cancer cells¹

Aldo Andreani^{a,*}, Stefania Bellini^a, Silvia Burnelli^a, Massimiliano Granaola^a, Alberto Leoni^a, Alessandra Locatelli^a, Rita Morigi^a, Mirella Rambaldi^a, Lucilla Varoli^a, Natalia Calonghi^b, Concettina Cappadone^b, Maddalena Zini^b, Claudio Stefanelli^b, Lanfranco Masotti^b, and Robert H. Shoemaker^c

^a Dipartimento di Scienze Farmaceutiche, Università di Bologna, Via Belmeloro 6, 40126 Bologna, Italy

^b Dipartimento di Biochimica "G. Moruzzi", Università di Bologna, Via Irnerio 48, 40126 Bologna, Italy

^c Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, MD 21702, USA

Abstract

The synthesis of new substituted *E*-3-(3-indolylmethylene)1,3-dihydroindol-2-ones is reported. The antitumor activity was evaluated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD. Structure-activity relationships are discussed. The action of selected compounds was investigated in MCF-7 breast cancer cells. The ability of these derivatives to inhibit cellular proliferation was accompanied by increased level of p53 and its transcriptional targets p21 and Bax, interference in the cell cycle progression with cell accumulation in the G2/M phase, and lastly activation of apoptosis.

Introduction

In the previous papers of this series^{2–6} we described several substituted *E*-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones prepared from an indolealdehyde and an oxindole. Compounds with potent cytotoxic activity were obtained when the aldehyde was 2-chloro-5-methoxy-6-methylindole-3-carbaldehyde,⁴ moreover we noticed⁶ that in some cases N-methylation increased the activity. Even preliminary attempts to introduce substituents at the positions 4, 5 and 6 of the oxindole portion had been performed.⁴

The rationale for the synthesis of new analogs described in this paper (Scheme 1, Table 1) is the following:

- Evaluation of the effects induced by different substituents in the oxindole portion (bromine, dimethylamino and succinyl group **4**, **5** e **6**), and by the position of

Corresponding author: - Tel. +39-51-2099714 fax: +39-51-2099734, aldo.andreani@unibo.it.

This material is available free of charge at <http://pubs.acs.org>.

Supporting Information Available

Additional IR and 1H-NMR spectra. Elemental analyses (Table S1), NSC numbers (Table S2), Antitumor activity expressed as the negative log of the molar concentration at three assay endpoints (Table S3). Mean graph of compound **30** where all the cell lines employed are reported (Figure S1).

chlorine (**7**): the compounds bearing chlorine at the position 4 or 5 were described in previous papers.^{5,6}

- Compound **8** was prepared to evaluate whether the methylation of the nitrogen in the chloroindole portion could lead to increase of activity as previously noticed.^{5,6} This kind of methylation was performed also in four compounds mentioned in the above group (**4–7**) and gave rise to the derivatives **9–12**.
- The synthesis of one compound bearing a methyl group at both the nitrogens and its activity on HeLa cells was described in the first paper of this series.² Its cytotoxicity was weak but when it was tested according to the NCI protocols it showed mean GI₅₀ 1.26 μ M. This prompted us to reconsider the possibility of bis-methylation and compounds **13–15** were prepared accordingly.
- Compound **16** was prepared to evaluate the effect of shifting methyl and methoxy group from the chloroindole to the oxindole portion.
- In the compounds so far described, the best results were obtained when the aldehyde was bearing a methoxy group at the 5 position and a methyl group at the 6 position. Compounds **17–22** were prepared to investigate if they could be replaced by different substituents and in particular with a group which can be easily protonated.
- In the previous paper⁶ good results were obtained with an additional condensed benzene ring in the oxindole portion. Compounds **23–28** bear an additional condensed benzene ring but in the chloroaldehyde portion.
- With the synthesis of compounds **29–34** we were planning to compare the activity of the 2-chloro with that of the unsubstituted derivatives.
- The introduction of a hydrophilic and electron attracting group was considered in compounds **35** and **36**.
- Compound **37** does not belong to the same series considered so far but could be the first term of a new series (devoid of the methine bridge) if it should display significant antitumor activity.

Chemistry

Most of the compounds were prepared by means of the single step Knoevenagel reaction between the indolinones **1** and the aldehydes **2** in methanol/piperidine. For compounds **4**, **6**, **11**, **24–26**, **35** and **37** a mixture of acetic acid/hydrochloric acid has been employed.

Most compounds were obtained as almost pure geometrical isomers which, according to the usual NOE experiments described in the previous papers^{7,8} were assigned to the E configuration. Compounds **18** and **34** were obtained as evident E/Z mixtures (around 70/30) and submitted as such to the biological tests. The E/Z ratio in solution is time dependent and tends to be 50/50. In our experience with similar derivatives, we described the separations of the two isomers by fractional crystallization⁷ but no significant difference in the pharmacological behavior was noticed.

The oxindoles **1d**, **1j**, **1o**, the aldehyde **2h** and the isatin **3** are commercially available whereas the other starting compounds (oxindoles and aldehydes) have been prepared according to the literature,^{4, 6, 9–22} except **1h**, **2d**, **2e** and **2j** reported under the experimental section.

Biology

a. Cell-based assays

In a preliminary test, compounds were assayed at a single high concentration (10^{-5} M) in the full NCI 60 cell panel. This panel is organized into subpanels representing leukemia, melanoma and cancers of lung, colon, kidney, ovary, breast, prostate and central nervous system. Only compounds which satisfy pre-determined threshold inhibition criteria in a minimum number of cell lines progress to the full 5-concentration assay. The threshold inhibition criteria for progression to the 5-concentration screen was selected to efficiently capture compounds with anti-proliferative activity based on the analysis of historical DTP screening data. The result is expressed as the percent growth of treated cells at the test concentration of 10^{-5} M following 48 h incubation (unpublished results).

Compounds **5**, **6**, **11**, **17**, **22**, **31**, **35**, **36** and **37** were not considered active enough to enter the 5- concentration test whereas all the others were subjected to this screen. The compounds were dissolved in dimethylsulphoxide (DMSO) and evaluated using five concentrations at ten-fold dilutions (the highest being 10^{-4} M) following 48 h incubation.

Table 2 reports the results obtained (vincristine is reported for comparison purposes), expressed as μ M concentration at three assay endpoints: the 50% growth inhibitory power (GI_{50}), the cytostatic effect (TGI =Total Growth Inhibition) and the cytotoxic effect (LC_{50}).

For some compounds the 5-concentration test was repeated and no significant differences were found. For these compounds the data reported in Table 2 are the mean values of the two experiments.

The tested compounds showed a mean GI_{50} range between 23.99 and 0.03 μ M and compounds **7**, **12**, **13**, **14**, **16**, **24**, **27**, **28** and **30** were submitted to BEC (Biological Evaluation Committee) for possible future development. Further studies continued at the NCI where the maximum tolerated dose (MTD) was determined for compounds **16**, **28** and **30**. It was found to be 100 mg/Kg for compound **16**, whereas it was found to be 400 mg/Kg for compounds **28** and **30** administered IP in DMSO for **16**, **28** and 10% DMSO in Saline/Tween 80 for **30**. Compound **30** was then chosen for the first in vivo experiment i.e. the "Hollow Fiber Assay",²³ which is a rapid and efficient initial in vivo screening model including multiple cell lines in a single assay. Therefore it was subjected to four experiments against a panel of three tumor cell lines each consisting of the breast, non-small cell lung, colon, ovarian, CNS and melanoma cell lines (administered IP in 10% DMSO and Saline/Tween 80). The cancer cell lines were loaded into biocompatible polyvinylidene fluoride hollow fibers. Duplicate sets of fibers were implanted into mice intraperitoneally (IP) and subcutaneously (SC) such that each mouse carried 3 fibers IP and 3 fibers SC representing 3 distinct cell lines. The mice were treated IP with compound **30** once daily for 4 days, the fibers are collected 24 h after treatment and the viable cell mass in each fiber is determined.

A point system was developed to assess the activity. A value of 2 is assigned for each treatment dose that results in a 50% or greater reduction in viable cell mass in any fiber. Compounds with a combined IP and SC score of 20 or higher, an SC score of 8 or higher, or cell kill of one or more cell lines are considered for further in vivo testing. Compound **30** resulted in a combined IP + SC score of 16, a SC score of 6 and gave cell kill nevertheless at this time BEC decided to suspend further testing.

In the light of the NCI-60 results, the following may be considered: shifting of chlorine from position 4/5 to 6 of the oxindole portion is accompanied by an activity increment which was

more evident when the indole portion was N-methylated. In fact compound **12** showed mean GI₅₀ 0.03 μ M vs. 5.37 of the 4-chloro isomer and 0.45 of the 5-chloro isomer.⁶

The comparison between the activity of compounds **7** and **12** (mean GI₅₀ 0.21 and 0.03 μ M respectively) confirms the activity increment observed for some analogs after N-methylation of the chloroaldehyde. To a lesser extent an increment was observed even in the comparison of **4** (mean GI₅₀ 2.14 μ M) vs **9** (1.66 μ M) and **5** (inactive in the preliminary test) vs **10** (11.22 μ M) whereas the same does not happen in the comparison of **8** (23.99 μ M) vs the previously reported NH free analog (2.00 μ M)⁴ and in the comparison of **13–15** vs the monomethyl derivatives.^{4,5} Shifting of the methyl and methoxy groups from the chloroindole to the oxindole portion (**16**) did not lead to a significant difference in the biological behavior: mean GI₅₀, TGI, LC₅₀ 0.45, 10.96, 56.23 μ M vs 0.40, 12.59, 79.43 μ M of the previously reported analog.⁴

The introduction of the dimethylamino group was accompanied by loss of activity with respect to the 5-methoxy-6-methyl analogs;⁵ compound **22**, bearing two dimethylamino groups, was inactive in the preliminary test. Other attempts were unsuccessful such as the introduction of hydrophilic/electron attracting groups or the lack of the methine bridge.

The evaluation of the antitumor activity of the compounds lacking chlorine at the 2-position of the indole portion (**29–34**) did not indicate that this class of compounds is superior to the 2-chloro derivatives: only compound **29** was more active than the corresponding 2-chloro analog (mean GI₅₀ 4.57 vs. 77.62 μ M³) whereas **30–34** were about as active as the chloro analogs: compound **30** was selected by NCI for in vivo studies.

The replacement of the indole by a benzindole portion led to the most interesting compounds: in particular **28** was the most active of the whole series described in this paper thus confirming that the bulky benzindole system is a suitable pharmacophoric group in this class of compounds.

b. Effect on growth of MCF-7 breast cancer cells

A subset of compounds was used for further assays in a biological model. Firstly, we examined the influence on the growth and death of MCF-7 breast cancer cells of compounds **12**, **28** (which in the 60 cell panel were very active) and **16**, a less-active compound.

Figure 1A shows that, even at a low concentration (200 nM), **12** and **28** blocked MCF-7 cell growth within 48 h. At the same concentration, the less effective compound **16** initially decreased cell proliferation, however after 24 h, the cells recovered and started to grow. In some preliminary experiments, apoptotic cell death was observed after a longer treatment time (72–96 h). At shorter times, a significant toxic effect became evident only at concentrations in the micromolar range, and cell death was detectable after a 48 h incubation (data not shown). To understand whether the toxicity of these new derivatives was associated with activation of apoptosis, the cells were treated with a 5 μ M concentration of the compounds, a concentration that caused about 30–40% of cell death, and the activation of caspases acting on the peptide substrate sequence Asp-Glu-Val-Asp (DEVD), was determined. This sequence is the optimal substrate for effector caspases 3, and 7, activated as the result of all caspase cascades.²⁴ However, since MCF-7 cells lack caspase 3, the assay measures mainly the activation of caspase 7, which is highly expressed in these cells.²⁵ The activation of the caspase proteases, considered the molecular effectors of apoptosis,²⁶ was significant only after 48 h of treatment (Figure 1B).

We next examined the effect of the derivatives on some biochemical pathways correlated with cell proliferation and cell death (Figure 2). In these studies, the cells were treated with

the different agents at 5 μ M concentration for 20 hours. Firstly, we determined whether the antiproliferative effect was accompanied by changes in the expression of the tumor suppressor p53. Figure 2A shows that compounds **12**, **16** and **28** caused a p53 increase. Next, we investigated the effect on ERK1/2 mitogen-activated protein kinases, which are generally associated with tumor cell growth.²⁷ In this case, the three compounds had different effects. In fact, **12** and especially **16** decreased ERK phosphorylation which, on the contrary, was increased by compound **28**. The three derivatives had minimal effects on the kinase Akt, an oncoprotein upregulated in several cancers and responsible for resistance to cell death,²⁸ Akt-phosphorylation was only slightly decreased by compound **12**.

These data indicate that interference in the function of growth-related kinases ERKs and Akt do not represent a common mechanism of the antiproliferative effect of the tested compounds, whereas p53 appears correlated to the action of these derivatives. To confirm the involvement of p53, the effects of the potent compound **12** on the levels of the p53 transcriptional target p21²⁹ were determined. In cells incubated 24 h with **12**, together with a threefold induction of p53, also p21 was increased by about 90% (Figure 2B). Another important protein associated to the tumor suppressive role of p53 is Bax, that is an effector of p53-induced apoptosis and is either a transcriptional target of p53 and a partner of p53 in its non-transcriptional actions.³⁰ The cellular content of the Bax protein was assayed by immunofluorescence microscopy. Figure 2C shows that treatment with compound **12** caused a considerable Bax accumulation, evidenced by a large increase in green fluorescence. Densitometric analysis of bands obtained by Western blotting (n=3) indicated an increase of 2.8 times (data not shown).

The p53 tumor suppressor can either cause apoptosis and influence the cell cycle.³¹ The increase of p21 caused by **12** suggested that the anticancer action of the novel compounds could be also associated with interference in cell cycle progression. Therefore, we examined the effect of some derivatives on the cell cycle profile of MCF-7 cells. The cells were incubated for 24 and 48 h in the presence of 200 nM of compounds **12** and **28**, and the analysis of DNA profiles was performed by flow cytometry. As previously detailed, at this concentration both compounds strongly inhibit cell growth, without causing massive cell death. Figure 3 shows that they caused a marked accumulation of MCF-7 cells in the G2/M phase, whereas the majority of control cells were in the G0/G1. Moreover, after treatment with the analogues, a notable cell population was observed in a sub-G1-peak caused by fragmented DNA in apoptotic cells. This population increased with incubation time, confirming activation of apoptosis.

In conclusion, the most active compounds tested on MCF-7 breast cancer cells gave rise to a block in cell cycle progression, with cell arrest in the G2/M phase. The arrest of the cell cycle probably causes the late induction of apoptosis, as indicated by activation of caspase proteases and appearance of a sub-G1 cell population. From the biochemical point of view, these events can be explained by the induction of the tumor suppressor p53, which is known to exert cell cycle blocking effect and eventual activation of apoptosis directly and by means of several effectors such as p21 or Bax,³¹ that were also increased.

Experimental Section

Chemistry

All the compounds prepared have a purity of at least 95% as determined by combustion analysis.

The melting points are uncorrected. TLC was performed on Bakerflex plates (Silica gel IB2-F) and column chromatography on Kieselgel 60 (Merck): the eluent was a mixture of

petroleum ether/acetone in various proportions. The IR spectra were recorded in nujol on a Nicolet Avatar 320 E.S.P.; $\nu_{\max}$ is expressed in cm^{-1} . The ^1H -NMR spectra were recorded on a Varian Gemini (300 MHz); the chemical shift (referenced to solvent signal) is expressed in δ (ppm) and J in Hz (abbreviations: ar=aromatic, bzind=benzindole, ind=indole, ox=oxindole). For the spectra that are not reported here, see Supporting Information. The oxindoles **1d**, **1j**, **1o**, the aldehyde **2h** and the isatin **3** are commercially available. The following compounds were prepared according to the literature: **1a**,⁹ **1b**,¹¹ **1c**,¹² **1e**,¹⁰ **1f**,¹³ **1g**,¹⁴ **1i**,¹⁶ **1k**,¹⁷ **1l**,¹⁸ **1m**,¹⁹ **1n**,⁴ **2a**,¹⁰ **2b**,⁶ **2c**,¹⁵ **2f**,²⁰ **2g**,²¹ and **35**.²²

Synthesis of 5-methoxy-1,6-dimethyl-1,3-dihydro-2H-indol-2-one (1h)—5-Methoxy-6-methyl-1,3-dihydro-2H-indol-2-one¹⁰ (4 mmol) in acetone (40 mL) was treated with dimethyl sulfate (9.5 mmol) in the presence of anhydrous potassium carbonate (6.5 mmol). The reaction mixture was refluxed for 15 h, cooled and filtered. The solution was evaporated and the expected compound was purified by column chromatography (petroleum ether/acetone, 70/30), with a yield of 52%. It was crystallized from acetone/petroleum ether: mp 93–95°C.

IR: 1697, 1240, 1151, 1069. ^1H -NMR: 2.17 (3H, s, CH_3), 3.06 (3H, s, N- CH_3), 3.47 (2H, s, CH_2), 3.73 (3H, s, OCH_3), 6.79 (1H, s, ar), 6.94 (1H, s, ar). Anal. Calcd for $\text{C}_{11}\text{H}_{13}\text{NO}_2$ (MW 191.23): C, 69.09; H, 6.85; N, 7.32. Found: C, 69.12; H, 6.78; N, 7.36.

Synthesis of 5-(dimethylamino)-3-[(dimethylamino)methylene]-2-oxoindoline-1-carbaldehyde (1p)—The Vilsmeier reagent was prepared at 0–5°C by dropping POCl_3 (32 mmol) into a stirred solution of DMF (43 mmol) in CHCl_3 (5 mL). 5-(Dimethylamino)-1,3-dihydroindol-2-one¹¹ (**1b**) (6 mmol) was dissolved in CHCl_3 and treated with the Vilsmeier reagent. After 3h at room temperature, CHCl_3 was evaporated under reduced pressure and the residue was poured into ice water. After neutralization with NaHCO_3 the expected compound was collected by filtration and crystallized from EtOH with a yield of 82%: mp 154–157°C.

I.R.: 1671, 1703, 1177, 1108. ^1H -NMR: 2.89 (6H, s, 2CH_3), 3.37 (3H, s, CH_3), 3.56 (3H, s, CH_3), 6.40 (1H, dd, ind-6, $J=8.6$, $J=2.6$), 6.85 (1H, d, ind-4, $J=2.6$), 7.69 (1H, d, ind-7, $J=8.6$), 7.85 (1H, s, CH), 9.14 (1H, s, CH). Anal. Calcd for $\text{C}_{14}\text{H}_{17}\text{N}_3\text{O}_2$ (MW 259.31): C, 64.85; H, 6.61; N, 16.20. Found: C, 64.87; H, 6.58; N, 16.23.

Synthesis of 2-chloro-5-(dimethylamino)-indole-3-carbaldehyde (2d)—Compound **1p** (2mmol) was refluxed for 15 min with POCl_3 (22 mmol). The mixture was cooled, poured into ice water and basified with 30% NH_4OH .³² The aldehyde **2d** was collected by filtration with a yield of 30%: mp 180–190°C dec.

I.R.: 3125, 1634, 830, 787. ^1H -NMR: 2.92 (6H, s, 2CH_3), 6.87 (1H, dd, ind-6, $J=8.7$, $J=2.4$), 7.28 (1H, d, ind-7, $J=8.7$), 7.39 (1H, d, ind-4, $J=2.4$), 9.95 (1H, s, CHO), 12.72 (1H, broad, NH). Anal. Calcd for $\text{C}_{11}\text{H}_{11}\text{ClN}_2\text{O}$ (MW 222.67): C, 59.33; H, 4.98; N, 12.58. Found: C, 59.29; H, 5.01; N, 12.60.

Synthesis of 2-chloro-1H-benzo[g]indole-3-carbaldehyde (2e) and 3-formyl-5-methoxy-6-methyl-1H-indole-2-carboxylic acid (2j)—The Vilsmeier reagent was prepared at 0–5°C by dropping POCl_3 (54 mmol) into a stirred solution of DMF (65 mmol) in CHCl_3 (5 mL). The 1,3-dihydro-2H-benzo[g]indol-2-one, prepared as reported in the literature³³ or 5-methoxy-6-methylindole-2-carboxylic acid³⁴ (5mmol) was suspended in CHCl_3 (20 mL) and treated with the Vilsmeier reagent. The reaction mixture was kept under reflux for 10–15 h, according to a TLC test. Chloroform was removed under reduced

pressure and the resulting oil was poured into ice. The crude aldehyde thus obtained was collected by filtration with a yield of 70%.

Data for **2e**. Crystallized from ethanol had mp 220–225°C.

I.R.: 3160, 1649, 856, 805. ¹H-NMR: 7.52 (1H, t, ar, J=7.9), 7.64 (1H, t, ar, J=7.9), 7.73 (1H, d, ar, J=7.9), 8.00 (1H, d, ar, J=7.9), 8.16 (1H, d, ar, J=7.9), 8.38 (1H, d, ar, J=7.9), 10.08 (1H, s, CHO), 13.77 (1H, s, NH). Anal. Calcd for C₁₃H₈ClNO (MW 229.66): C, 67.99; H, 3.51; N, 6.10. Found: C, 68.02; H, 3.49; N, 6.13.

Data for **2j**. Crystallized from methanol had mp 260°C dec.

I.R.: 3247, 1672, 1643, 1102, 1025. ¹H-NMR: 2.26 (3H, s, CH₃), 3.83 (3H, s, OCH₃), 7.30 (1H, s, ind-4/7), 7.64 (1H, s, ind-4/7), 10.60 (1H, s, CHO), 12.52 (1H, s, NH), 13.20 (1H, broad, COOH). Anal. Calcd for C₁₂H₁₁NO₄ (MW 233.22): C, 61.80; H, 4.75; N, 6.01. Found: C, 61.82; H, 4.73; N, 5.98.

General procedure for the synthesis of compounds 5, 7–10, 12–23, 27–34 and 36—The appropriate 2-indolinone **1** (10 mmol) was dissolved in methanol (100 mL) and treated with the equivalent of the appropriate indole-3-carbaldehyde **2** and piperidine (1 mL). The reaction mixture was refluxed for 3–5 h (according to a TLC test) and the precipitate formed on cooling was collected by filtration with a yield of 20% for compound **5**, **7**, **28** and **33**, 45–50% for compounds **13**, **15**, **16**, **23**, **27** and **31** and 75–85% for compounds **8–10**, **12**, **14**, **29**, **30**, **32**, **34** and **36**.

Compounds **17–22** were purified by column chromatography with a yield of 20%.

Data for **7**. I.R.: 3355, 1667, 1593, 1207, 917. ¹H-NMR: 2.25 (3H, s, CH₃), 3.56 (3H, s, OCH₃), 6.47 (1H, s, ind-4), 6.76 (1H, d, ox-4, J=8.2), 6.89 (1H, d, ox-7, J=1.8), 6.95 (1H, dd, ox-5, J=8.2, J=1.8), 7.23 (1H, s, ind-7), 7.69 (1H, s, CH), 10.71 (1H, s, NH-ox), 12.60 (1H, broad, NH-ind). Anal. C₁₉H₁₄Cl₂N₂O₂ (C, H, N).

Data for **9**. I.R.: 3150, 1692, 1594, 1298, 922. ¹H-NMR: 2.32 (3H, s, CH₃), 3.62 (3H, s, N-CH₃), 3.86 (3H, s, OCH₃), 6.48 (1H, s, ind-4), 6.86 (2H, m, ind+ox), 7.35 (1H, d, ox, J=8.4), 7.52 (1H, s, ox), 7.74 (1H, s, CH), 10.73 (1H, s, NH-ox). Anal. C₂₀H₁₆BrClN₂O₂ (C, H, N).

Data for **12**. I.R.: 3140, 1714, 1611, 1040, 799. ¹H-NMR: 2.29 (3H, s, CH₃), 3.56 (3H, s, N-CH₃), 3.82 (3H, s, OCH₃), 6.50 (1H, s, ind-4), 6.74 (1H, d, ox-4, J=7.5), 6.89 (1H, d, ox-7, J=1.2), 6.92 (1H, dd, ox-5, J=7.5, J=1.2), 7.48 (1H, s, ind-7), 7.68 (1H, s, CH), 10.74 (1H, s, NH-ox). Anal. C₂₀H₁₆Cl₂N₂O₂ (C, H, N).

Data for **13**. I.R.: 1709, 1605, 1040, 912, 851. ¹H-NMR: 2.30 (3H, s, CH₃), 3.34 (3H, s, N-CH₃), 3.53 (3H, s, N-CH₃), 3.84 (3H, s, OCH₃), 6.52 (1H, s, ind-4), 6.83 (1H, d, ox-4/7, J=7.2), 6.94 (1H, t, ox-5/6, J=7.2), 7.05 (1H, d, ox-4/7, J=7.2), 7.29 (1H, t, ox-5/6, J=7.2), 7.49 (1H, s, ind-7), 7.73 (1H, s, CH). Anal. C₂₁H₁₉ClN₂O₂ (C, H, N).

Data for **14**. I.R.: 3155, 1667, 1592, 1119, 912. ¹H-NMR: 2.31 (3H, s, CH₃), 3.19 (3H, s, N-CH₃), 3.60 (3H, s, N-CH₃), 3.84 (3H, s, OCH₃), 6.40 (1H, d, ox-4, J=2.3), 6.57 (1H, s, ind-4), 6.68 (1H, dd, ox-6, J=8.2, J=2.3), 6.83 (1H, d, ox-7, J=8.2), 7.48 (1H, s, ind-7), 7.68 (1H, s, CH), 8.94 (1H, s, OH). Anal. C₂₁H₁₉ClN₂O₃ (C, H, N).

Data for **16**. I.R.: 1686, 1602, 1052, 897, 739. ¹H-NMR: 2.17 (3H, s, CH₃), 3.20 (3H, s, N-CH₃), 3.25 (3H, s, OCH₃), 6.43 (1H, s, ox), 6.88 (1H, s, ox), 7.22 (3H, m, ind), 7.46 (1H, d, ind, J=7.8), 7.64 (1H, s, CH), 12.78 (1H, broad, NH-ind). Anal. C₂₀H₁₇ClN₂O₂ (C, H, N).

Data for **18**. I.R.: 3165, 1692, 1600, 1215, 804. $^1\text{H-NMR}$: 2.74 (6H, s, $\text{N}(\text{CH}_3)_2$), 6.20 (1H, d, ox/ind-4, $J=2.2$), 6.70 (1H, d, ox/ind-4, $J=2.2$), 6.89 (1H, d, ox/ind-7, $J=8.4$), 6.92 (1H, dd, ox/ind-6, $J=8.4$, $J=2.2$), 7.21 (1H, dd, ox/ind-6, $J=8.4$, $J=2.2$), 7.34 (1H, d, ox/ind-7, $J=8.4$), 7.74 (1H, s, CH), 10.69 (1H, s, NH-ox), 12.60 (1H, broad, NH-ind). Anal. $\text{C}_{19}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}$ (C, H, N).

Data for **20**. I.R.: 3135, 1683, 1608, 1199, 810. $^1\text{H-NMR}$: 2.72 (6H, s, $\text{N}(\text{CH}_3)_2$), 3.43 (3H, s, OCH_3), 6.25 (1H, d, ind/ox-4, $J=2.2$), 6.39 (1H, s, ind/ox), 6.77 (2H, s, ind/ox), 6.89 (1H, dd, ind/ox-6, $J=9$, $J=2.2$), 7.31 (1H, d, ind/ox-7, $J=9$), 7.65 (1H, s, CH), 10.36 (1H, s, NH-ox), 12.70 (1H, broad, NH-ind). Anal. $\text{C}_{20}\text{H}_{18}\text{ClN}_3\text{O}_2$ (C, H, N).

Data for **27**. I.R.: 3408, 3172, 1721, 1674, 1086. $^1\text{H-NMR}$: 2.11 (3H, s, CH_3), 3.17 (3H, s, OCH_3), 6.49 (1H, s, ox), 6.68 (1H, s, ox), 7.31 (1H, d, bzind, $J=8.1$), 7.48 (2H, t, bzind, $J=8.1$), 7.61 (2H, m, bzind+CH), 7.96 (1H, d, bzind, $J=8.1$), 8.42 (1H, d, bzind, $J=8.1$), 10.35 (1H, s, NH-ox), 13.46 (1H, broad, NH-bzind). Anal. $\text{C}_{23}\text{H}_{17}\text{ClN}_2\text{O}_2$ (C, H, N).

Data for **28**. I.R.: 3200, 1666, 1583, 805, 671. $^1\text{H-NMR}$: 3.19 (3H, s, CH_3), 6.39 (1H, d, ox-4, $J=2.3$), 6.68 (1H, dd, ox-6, $J=8.4$, $J=2.3$), 6.84 (1H, d, ox-7, $J=8.4$), 7.28 (1H, d, bzind, $J=8.1$), 7.50 (1H, t, bzind, $J=8.1$), 7.60 (1H, d, bzind, $J=8.1$), 7.62 (1H, t, bzind, $J=8.1$), 7.70 (1H, s, CH), 7.99 (1H, d, bzind, $J=8.1$), 8.39 (1H, d, bzind, $J=8.1$), 8.82 (1H, s, OH), 13.45 (1H, s, NH-bzind). Anal. $\text{C}_{22}\text{H}_{15}\text{ClN}_2\text{O}_2$ (C, H, N).

Data for **30**. I.R.: 3364, 3131, 1684, 1603, 1100. $^1\text{H-NMR}$: 2.27 (3H, s, CH_3), 3.93 (3H, s, OCH_3), 6.83 (1H, d, ox-4/7, $J=7.5$), 6.98 (1H, t, ox-5/6, $J=7.5$), 7.12 (1H, t, ox-5/6, $J=7.5$), 7.27 (1H, s, ind), 7.67 (1H, s, ind), 7.92 (1H, d, ox-4/7), 8.14 (1H, s, CH), 9.33 (1H, s, ind-2), 10.47 (1H, s, NH-ox), 11.78 (1H, broad, NH-ind). Anal. $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}_2$ (C, H, N).

General procedure for the synthesis of compounds **4**, **6**, **11**, **24–26** and **37**—

The appropriate oxindole **1** (5 mmol) was dissolved in acetic acid (25 mL) and treated with an equivalent of indole-3-carbaldehyde **2** or 5-methoxyindole-2,3-dione **3** (for compound **37**) and 37% hydrochloric acid (1 mL). The reaction mixture was refluxed for 24 h and, after cooling, the precipitate was collected by filtration with a yield of 35–40% for compounds **4**, **24–26** and 70–80% for compounds **6**, **11** and **37**.

Data for **4**. I.R.: 3124, 1672, 1604, 1108, 1021. $^1\text{H-NMR}$: 2.28 (3H, s, CH_3), 3.62 (3H, s, OCH_3), 6.48 (1H, s, ind-4), 6.86 (1H, d, ox-7, $J=8.2$), 6.90 (1H, d, ox-4, $J=1.5$), 7.27 (1H, s, ind-7), 7.36 (1H, dd, ox-6, $J=8.2$, $J=1.5$), 7.73 (1H, s, CH), 10.74 (1H, s, NH-ox), 12.77 (1H, broad, NH-ind). Anal. $\text{C}_{19}\text{H}_{14}\text{BrClN}_2\text{O}_2$ (C, H, N).

Data for **24**. I.R.: 3426, 1698, 1623, 1198, 809. $^1\text{H-NMR}$: 6.79 (1H, d, ox-4, $J=2.3$), 6.89 (1H, d, ox-7, $J=8.3$), 7.22 (1H, dd, ox-6, $J=8.3$, $J=2.3$), 7.28 (1H, d, bzind, $J=8.2$), 7.51 (2H, t, bzind, $J=8.2$), 7.63 (1H, d, bzind, $J=8.2$), 7.77 (1H, s, CH), 8.00 (1H, d, bzind, $J=8.2$), 8.43 (1H, d, bzind, $J=8.2$), 10.76 (1H, s, NH-ox), 13.55 (1H, broad, NH-bzind). Anal. $\text{C}_{21}\text{H}_{12}\text{Cl}_2\text{N}_2\text{O}$ (C, H, N).

Data for **25**. I.R.: 3200, 1607, 1170, 815, 682. $^1\text{H-NMR}$: 6.57 (1H, dd, ox, $J=9$, $J=2.7$), 6.88 (1H, dd, ox, $J=8$, $J=4.5$), 7.04 (1H, td, ox, $J=9$, $J=2.7$), 7.30 (1H, d, bzind, $J=8.3$), 7.53 (2H, m, bzind), 7.63 (1H, d, bzind, $J=8.3$), 7.77 (1H, s, CH), 8.00 (1H, d, bzind, $J=8.3$), 8.44 (1H, d, bzind, $J=8.3$), 10.65 (1H, s, NH-ox), 13.56 (1H, broad, NH-bzind). Anal. $\text{C}_{21}\text{H}_{12}\text{ClFN}_2\text{O}$ (C, H, N).

Biology

a. Cell-based Screening Assay—The NCI screening is a two stage process,³⁵ beginning with the evaluation of all compounds against the 60 cell lines at a single concentration of 10^{-5} M. Compounds exhibiting significant growth inhibition were evaluated against the 60 cell panel at five concentration levels by the NCI according to standard procedures (<http://dtp.nci.nih.gov/branches/btb/ivclsp.html>). In both cases the exposure time was 48h.

b. Acute Toxicity—To a single female athymic nude mouse (APA) was given a single injection of 400 mg/Kg; a second mouse received a dose of 200 mg/Kg and a third mouse received a dose of 100 mg/kg of compounds **16**, **28** and **30**. The mice were allowed ad libitum feed and water and they were observed for 2 weeks. The doses of compound **16** were administered IP in DMSO. After 14 days the mice treated with 400 and 200 mg/kg were sacrificed since they had lost more than 20% of their body weight. Therefore MTD was 100 mg/Kg. The doses of compound **28** and **30** were administered IP in DMSO and DMSO in Saline/Tween 80 respectively. After 14 days no mice showed weight loss or other signs of significant toxicity, therefore MTD was 400 mg/Kg.

c. Hollow Fiber Assay—Twelve tumor cell lines (NCI-H23, NCI-H522, MDA-MB-231, MDA-MB-435, SW-620, COLO 205, LOX, UACC-62, OVCAR-3, OVCAR-5, U251 and SF-295) were cultivated in RPMI-1640 containing 10% FBS and 2 mM glutamine. On the day preceding hollow fiber preparation, the cells were given a supplementation of fresh medium to maintain log phase growth. For fiber preparation, the cells were harvested by standard trypsinization technique and resuspended at the desired cell density ($2-10 \times 10^6$ cells/ml). The cell suspension was flushed into 1 mm (internal diameter) polyvinylidene fluoride hollow fibers with a molecular weight exclusion of 500,000 Da. The hollow fibers were heat-sealed at 2 cm intervals and the samples generated from these seals were placed into tissue culture medium and incubated at 37°C in 5% CO₂ for 24 to 48 hours prior to implantation. A total of three different tumor lines were prepared for each experiment so that each mouse received three intraperitoneal implants (one of each tumor line) and three subcutaneous implants (one of each tumor line). On the day of implantation, samples of each tumor cell line preparation were quantitated for viable cell mass by a stable endpoint MTT assay so that the time zero cell mass is known. Mice were treated with compound **30** starting on day 4 after fiber implantation and continuing daily for 4 days. The compound was administered by IP injection at two dose levels: 150 mg/Kg and 100.5 mg/Kg. The vehicle was 10% DMSO in saline/0.05% Tween 80. The fibers were collected from the mice on the day following the fourth treatment and subjected to the stable endpoint MTT assay. The optical density of each sample was determined spectrophotometrically at 540 nm and the mean of each treatment group was calculated. The percent net growth for each cell line in each treatment group was calculated and compared to the percent net growth in the vehicle treated controls. A 50% or greater reduction in percent growth of the treated samples compared to the vehicle control samples was considered a positive result. Each positive result was given a score of 2 and all of the scores were totaled. The maximum possible score for the described experiment is 96 (12 cell lines x 2 sites x 2 dose levels x 2 [score]).

d. Cell culture and treatment—The human breast adenocarcinoma cell line MCF-7 was maintained in RPMI 1640 medium (Euroclone, Italy), supplemented with 10% FBS (Euroclone, Italy) and 2 mM L-glutamine (Sigma, USA) at 37°C and 5% CO₂. Working solutions of compounds under test were prepared in DMSO at 10 mmol/L immediately before use. Cells were plated at 2×10^4 cells/cm² in plastic culture wells and after 24 hours the derivatives were added to the medium to obtain the indicated concentrations. In control cells, DMSO was added to the culture medium. At the end of the treatment, cells were

harvested using 0.11 % trypsin (Sigma, USA) 0.02% EDTA (Sigma, USA) and counted. Cell viability was determined by trypan blue exclusion.

e. Cell cycle analysis—MCF-7 control and treated cells were detached with 0.11% trypsin (Sigma-Aldrich, St Louis MO), 0.02% EDTA, washed twice in PBS and centrifuged. The pellet was suspended in 0.01% nonidet P-40 (Sigma, USA) 10 µg/mL RNase, and 0.1% sodium citrate (Sigma USA) and 50µg/mL propidium iodide (PI) (Sigma, USA), for 30 min at room temperature in the dark. Propidium iodide fluorescence was analyzed using a Brite flow cytometer (Biorad) and cell cycle analysis was performed by means of a Coulter Epics XL MCL Cytometer. Cell cycle analysis was performed using Modfit 5.0 software.

f. Western blotting—The cells were collected in 5 mM dithiothreitol, 2 mM EDTA, 0.1% CHAPS, 0.1% Triton X-100, and protease inhibitors in 20 mM HEPES pH 7.5 and subjected to two cycles of freeze-thawing. The cell proteins in the homogenate were extracted, separated by SDS-PAGE, and detected as described.³⁶ Primary antibodies against total and phosphorylated ERK 1/2 and Akt were from Cell Signaling Technology, Danvers, MA; anti-p53, anti-p21 and anti β -actin antibodies were from Santa Cruz Biotechnology, Santa Cruz, CA. Quantitative assay of immunoblotting was obtained by densitometry with a Fluor-S Max Multimager instrument (Bio-Rad).

g. Immunofluorescence confocal microscopy—MCF-7 cells seeded at 1×10^4 cells/cm² on glass coverslips. At the end of the incubation, cells were washed twice and fixed with 3% *p*-formaldehyde, washed with 0.1 M glycine in PBS and permeabilized in 70% ice-cold ethanol. Bax staining was obtained by incubation for 1 h at room temperature with a mouse monoclonal anti-Bax antibody (BioSource). Cells were then washed, incubated with FITC-conjugated anti-mouse IgG antibody (Sigma) for 1 h and finally stained with propidium iodide. All preparations were embedded in Mowiol and analyzed using a Nikon C1s confocal laser-scanning microscope, equipped with Nikon eclipse TE300. Multiple images were acquired by using sequential laser excitations at 488 nm and 568 nm to reduce spectral bleed-through artifacts.

h. Caspase activity—The activity of caspase enzymes hydrolyzing the peptide sequence DEVD, indicated as DEVDase activity, was measured in cell extracts by a fluorometric assay.³⁶

i. Data analysis—All the shown experiments about the effects of studied compounds on MCF-7 cells were performed independently three or four times with comparable results. The results are expressed as means $\pm$ s.e.m. of the data obtained in the indicated numbers of independent experiments. When statistical analysis was applicable, data were compared by Student t-test. Differences were considered significant for $P < 0.05$.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work has been supported by a grant from the University of Bologna (RFO). We are grateful to the National Cancer Institute (Bethesda, MD) for the anticancer tests.

Abbreviations

NCI	National Cancer Institute
DTP	Developmental Therapeutics Program
GI	growth inhibition
TGI	total growth inhibition
LC	lethal concentration
BEC	Biological Evaluation Committee
MTD	maximum tolerated dose
DMSO	dimethyl sulfoxide
FITC	fluorescein isothiocyanate
EDTA	ethylenediaminetetraacetic
FBS	fetal bovine serum
PBS	phosphate-buffered saline
PI	propidium iodide

References

1. Potential Antitumor Agents 46. For part 45, see the following: Andreani A, Burnelli S, Granaola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Landi L, Prata C, Vieceli Dalla Sega F, Caliceti C, Shoemaker RH. Antitumor Activity and COMPARE Analysis of Bis-indole Derivatives. *Bioorg Med Chem*. In press. 10.1016/j.bmc.2010.03.063
2. Andreani A, Locatelli A, Rambaldi M, Leoni A, Bossa R, Fraccari A, Galatulas I. Potential Antitumor Agents. 25. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones. *Anticancer Res*. 1996; 16:3585–3588. [PubMed: 9042225]
3. Andreani A, Locatelli A, Leoni A, Morigi R, Chiericozzi M, Fraccari A, Galatulas I, Salvatore G. Synthesis and Potential Coanthracyclinic Activity of Pyridylmethylene and Indolylmethylene Lactams. *Eur J Med Chem*. 1998; 33:905–909.
4. Andreani A, Granaola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Garaliene V. Synthesis and Antitumor Activity of 1,5,6-Substituted 3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones. *J Med Chem*. 2002; 45:2666–2669. [PubMed: 12036377]
5. Andreani A, Granaola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Garaliene V, Farruggia G, Masotti L. Substituted *E*-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones With Antitumor Activity. *Bioorg Med Chem*. 2004; 12:1121–1128. [PubMed: 14980624]
6. Andreani A, Burnelli S, Granaola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Farruggia G, Zini M, Stefanelli C, Masotti L. Substituted *E*-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with Antitumor Activity: Effect on the Cell Cycle and Apoptosis. *J Med Chem*. 2007; 50:3167–3172. [PubMed: 17559205]
7. Andreani A, Locatelli A, Leoni A, Rambaldi M, Morigi R, Bossa R, Chiericozzi M, Fraccari A, Galatulas I. Synthesis and Potential Coanthracyclinic Activity of Substituted 3-(5-Imidazo[2,1-b]thiazolylmethylene)-2-indolinones. *Eur J Med Chem*. 1997; 32:919–924.
8. Andreani A, Granaola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Giorgi G, Salvini L, Garaliene V. Synthesis and Antitumor Activity of Substituted 3-(5-Imidazo[2,1-b]thiazolylmethylene)-2-indolinones. *Anticancer Drug Design*. 2001; 16:167–174.
9. Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, Tang C. Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors that Exhibit Selectivity toward Particular Receptor Tyrosine Kinases. *J Med Chem*. 1998; 41:2588–2603. [PubMed: 9651163]

10. Andreani A, Rambaldi M, Bonazzi D, Greci L, Andreani F. Potential Antitumor Agents. III. Hydrazone Derivatives of 5-Substituted 2-Chloro-3-formyl-6-methylindole. *Farmaco*. 1979; 34:132–138.
11. Minisci F, Galli R, Cecere M. Amminazione Radicalica di Composti Aromatici Attivati: Acetammidi. Nuovo Processo per la Sintesi di *para*-Ammino-N,N-dialchilaniline. *La Chimica e l'Industria*. 1966; 48:1324–1326.
12. Nakagawa, K.; Sato, T.; Nishi, T.; Oshiro, Y.; Yamamoto, K. Carbostyryl and Oxindole Derivatives. *Jpn. Kokai Tokkyo Koho*. CODEN: JKXXAF JP 52073866 19770621 Showa. 1977. p. 5 Patent written in Japanese. Application: JP 75–150935 19751216. CAN 87:167899 AN 1977:567899 CAPLUS
13. Hodges R, Shannon JS, Jamieson WD, Taylor A. Chemical and Biological Properties of Some Oxindol-3-ylidene Methines. *Can J Chem*. 1968; 46:2189–2194.
14. Porter JC, Robinson R, Wyler M. Monothiophthalimide and Some Derivatives of Oxindole. *J Chem Soc*. 1941:620–624.
15. Schulte KE, Reisch J, Stoess U. Chloroformylation of α -Pyrrolones. *Angew Chemie, Int Ed*. 1965; 4:1081–1082.
16. Romeo A, Corrodi H, Hardegger E. Umsetzungen des o-Nitrophenylessigesters und des 2-Chlor-6-nitro-phenyl-brenztraubensäureesters. *Helv Chim Acta*. 1955; 38:463–467.
17. Beer RJS, Davenport HF, Robertson A. Extensions of the Synthesis of Hydroxyindoles from p-Benzoquinones. *J Chem Soc*. 1953:1262–1264.
18. Koelsch CF. A Synthesis of Ethyl Quininate from m-Cresol. *J Amer Chem Soc*. 1944; 66:2019–2020.
19. Zakrzewska A, Kolehmainen E, Osmialowski B, Gawinecki R. 4-Fluoroanilines: Synthesis and Decomposition. *J Fluorine Chem*. 2001; 111:1–10.
20. Steven E, Kloor SE, Cassady JM. An Intramolecular Photocyclization to from the Azepino [3,4,5-cd] Indole System. *Synth Commun*. 1988; 18:671–674.
21. Allen GR, Binovi LJ, Weiss MJ. The Mitomycin Antibiotics. *Synthetic Studies*. XVI. The Utilization of 5-Methoxy-4-nitro-3-indolecarboxaldehydes for the Synthesis of Related 4,7-Indoloquinones. *J Med Chem*. 1967; 10:7–13. [PubMed: 6031708]
22. Buzzetti F, Pinciroli V, Brasca MG, Crugnola A, Fustinoni S, Longo A. Synthesis and Configuration of Some New Bicyclic 3-Arylidene- and 3-Heteroarylidene-2-oxindoles. *Gazz Chim Ital*. 1995; 125:69–75.
23. Hollingshead M, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR. In Vivo Cultivation of Tumor Cells in Hollow Fibers. *Life Sciences*. 1995; 57:131–141. [PubMed: 7603295]
24. Nicholson DW, Thornberry NA. Caspases: Killer Proteases. *Trends Biochem Sci*. 1997; 22:299–306. [PubMed: 9270303]
25. Jänicke RU, Ng P, Sprengart ML, Porter AG. Caspase-3 is required for α -fodrin Cleavage but Dispensable for Cleavage of other Death Substrates in Apoptosis. *J Biol Chem*. 1998; 273:15540–15545.
26. Kurokawa M, Kornbluth S. Caspases and Kinases in a Death Grip. *Cell*. 2009; 138:838–854. [PubMed: 19737514]
27. Balmano K, Cook SJ. Tumour Cell Survival Signalling by the ERK1/2 Pathway. *Cell Death Differ*. 2009; 16:368–377. [PubMed: 18846109]
28. Engelman JA. Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations. *Nat Rev Cancer*. 2009; 9:550–562. [PubMed: 19629070]
29. Abbas T, Dutta A. p21 in Cancer: Intricate Networks and Multiple Activities. *Nat Rev Cancer*. 2009; 9:400–414. [PubMed: 19440234]
30. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent Pro-apoptotic Functions of p53. *Curr Opin Cell Biol*. 2005; 17:631–636. [PubMed: 16226451]
31. Kuribayashi K, El-Deiry WS. Regulation of Programmed Cell Death by the p53 Pathway. *Adv Exp Med Biol*. 2008; 615:201–221. [PubMed: 18441595]

32. Engqvist R, Javaid A, Bergman J. Synthesis of Thienodolin. *Eur J Org Chem.* 2004; 12:2589–2592.
33. Mayer F, Oppenheimer T. Über Naphthyl-essigsäuren. 3. Abhandlung: 1-Nitronaphthyl-2-brenztraubensäure und 1-Nitronaphthyl-2-essigsäure. *Chem Ber.* 1918; 51:1239–1245.
34. Allen GR, Poletto JF, Weiss MJ. The Mitomycin Antibiotics. *Synthetic Studies. V. Preparation of 7-Methoxymitosene.* *J Org Chem.* 1965; 30:2897–2904. [PubMed: 5846139]
35. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. *J Natl Cancer Inst.* 1991; 83:757–766. [PubMed: 2041050]
36. Zini M, Passariello CL, Gottardi D, Cetrullo S, Flamigni F, Pignatti C, Minarini A, Tumiatti V, Milelli A, Melchiorre C, Stefanelli C. Cytotoxicity of Methoctramine and Methoctramine-related Polyamines. *Chem Biol Interact.* 2009; 181:409–416. [PubMed: 19576191]

Figure 1.

Effects on growth and death of MCF-7 cells. (A) Rate of cell growth determined as total cell number. The cells were incubated in the presence of the indicated compounds (200 nM) and viable cells were counted daily. The differences of all treated cells vs control cells were significant ($P < 0.05$) at either 24 and 48 h. (B) Caspase activity acting on the peptide sequence DEVD (mainly caspase 7) was measured in extracts obtained from cells treated for 24 or 48 h with the indicated compounds (5 μ M). The reported data are means $\pm$ s.e.m. obtained in five determinations. The differences of all treated cells vs. control cells were significant ($P < 0.05$) only at 48 h.

Figure 2

. Effect on biochemical pathways correlated with cell growth in MCF-7 cells. (A) The cells were incubated for 20 h in the presence of 5 μ M of the indicated compound. Then the content and phosphorylation status of the indicated proteins were determined in cell extracts by Western blotting (80 μ g of protein/lane). Immunoblots reported are from one experiment representative of at least three that gave similar results. (B) Quantitative determination of p53 and p21 proteins by densitometry of immunoblotting in cells incubated 24 h in the presence of 5 μ M compound **12**. Results are means $\pm$ s.e.m. obtained in four separate determinations. Differences between treated cells and control cells were significant ($P < 0.05$) for both p53 and p21. (C) Effect of compound **12** (5 μ M for 24 h) on cellular Bax detected by immunofluorescence confocal microscopy. Nuclei were evidenced by incubation with propidium iodide (red fluorescence). Bax was stained with FITC-antibody and is evidenced as green fluorescence. The image is representative of three experiments.

Figure 3.

Effects on cell cycle in MCF-7 cells. Cells were treated with 200 nM of the indicated compound for 24 h, afterward cell cycle distribution was determined by flow cytometry. Results are means $\pm$ s.e.m. of three determinations.

DMA = dimethylamino, Succ = succinyl, CBR = condensed benzene ring.

Comp	Starting compound 1				Starting compound 2 or 3			
4	R	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇
1a ¹	H	H	Br	H	2a ¹⁰	H	Cl	OCH ₃ CH ₃ H
5	1b ¹¹	H	H	DMA	H	2a	H	Cl
6	1c ¹²	H	H	Succ	H	2a	H	Cl
7	1d	H	H	H	Cl	2a	H	Cl
8	1e ¹³	H	OCH ₃	CH ₃ 2d ¹⁴	CH ₃	Cl	OCH ₃	CH ₃ H
9	1a	H	H	Br	H	2b	CH ₃	Cl
10	1b	H	H	DMA	H	2b	CH ₃	Cl
11	1c	H	H	Succ	H	2b	CH ₃	Cl
12	1d	H	H	H	Cl	2b	CH ₃	Cl
13	1e ¹⁵	CH ₃	H	H	H	2b	CH ₃	Cl
14	1g ¹⁶	CH ₃	H	OH	H	2b	CH ₃	Cl
15	1b	CH ₃	H	OCH ₃	CH ₃ 2b	CH ₃	Cl	OCH ₃ CH ₃ H
16	1b	CH ₃	H	OCH ₃	CH ₃ 2c ¹⁷	H	Cl	H
17	1f ¹⁸	H	Cl	H	H	2d	H	Cl
18	1j	H	H	Cl	H	2d	H	Cl
19	1k ¹⁷	H	H	OH	H	2d	H	Cl
20	1f ¹⁸	H	H	OCH ₃	H	2d	H	Cl
21	1g	CH ₃	H	OH	H	2d	H	Cl
22	1b	H	H	DMA	H	2d	H	Cl
23	1i	H	Cl	H	H	2e	H	Cl
24	1j	H	H	Cl	H	2e	H	Cl
25	1m ¹⁹	H	H	F	H	2e	H	Cl
26	1a ¹	H	H	OH	CH ₃ 2e	H	Cl	H
27	1e	H	H	OCH ₃	CH ₃ 2e	H	Cl	H
28	1g	CH ₃	H	OH	H	2e	CH ₃	Cl
29	1a	H	H	H	H	2f ²⁰	H	H
30	1e	H	H	H	H	2g ²¹	H	H
31	1e	H	H	OCH ₃	CH ₃ 2g	H	H	H
32	1e	H	H	OCH ₃	CH ₃ 2h	H	H	H
33	1f	CH ₃	H	H	H	2g	H	H
34	1g	CH ₃	H	OH	H	2g	H	H
35 ²²	1e	H	H	H	H	2i	H	H
36	1e	H	H	H	H	2j	H	H
37	1i	H	H	OCH ₃	H	H	COOH	CH ₃ CH ₃ H

Scheme 1.

Table 1

Compounds 4–37

Comp	Formula	MW	Mp, °C	Comp	Formula	MW	Mp, °C
4	C ₁₉ H ₁₄ BrClN ₂ O ₂	417.69	325–328 dec.	21	C ₂₀ H ₁₈ ClN ₃ O ₂	367.83	200–205 dec.
5	C ₂₁ H ₂₀ ClN ₃ O ₂	381.86	295–298 dec.	22	C ₂₁ H ₂₁ ClN ₄ O	380.87	340–343 dec.
6	C ₂₃ H ₁₉ ClN ₂ O ₅	438.86	338–340	23	C ₂₁ H ₁₂ Cl ₂ N ₂ O	379.24	278–281 dec.
7	C ₁₉ H ₁₄ Cl ₂ N ₂ O ₂	373.23	285–290 dec.	24	C ₂₁ H ₁₂ Cl ₃ N ₂ O	379.24	310–312 dec.
8	C ₂₂ H ₂₁ ClN ₂ O ₃	396.87	284–286 dec.	25	C ₂₁ H ₁₂ ClFN ₂ O	362.79	330–332 dec.
9	C ₂₀ H ₁₆ BrClN ₂ O ₂	431.71	290–292 dec.	26	C ₂₂ H ₁₅ ClN ₂ O ₂	374.82	185–187 dec.
10	C ₂₂ H ₂₂ ClN ₃ O ₂	395.88	230–233 dec.	27	C ₂₃ H ₁₇ ClN ₂ O ₂	388.85	317–320 dec.
11	C ₂₄ H ₂₁ ClN ₂ O ₅	452.89	340–345 dec.	28	C ₂₂ H ₁₅ ClN ₂ O ₂	374.82	335–338 dec.
12	C ₂₀ H ₁₆ Cl ₂ N ₂ O ₂	387.26	250–253 dec.	29	C ₁₈ H ₁₄ N ₂ O ₂	290.32	255–258
13	C ₂₁ H ₁₉ ClN ₂ O ₂	366.84	277–280 dec.	30	C ₁₉ H ₁₆ N ₂ O ₂	304.34	288–290
14	C ₂₁ H ₁₉ ClN ₂ O ₃	382.84	348–350 dec.	31	C ₂₁ H ₂₀ N ₂ O ₃	348.40	273–275
15	C ₂₃ H ₂₃ ClN ₂ O ₃	410.90	225–228	32	C ₁₉ H ₁₆ N ₂ O ₂	304.34	272–275
16	C ₂₀ H ₁₇ ClN ₂ O ₂	352.82	220–222 dec.	33	C ₂₀ H ₁₈ N ₂ O ₂	318.37	277–280
17	C ₁₉ H ₁₅ Cl ₂ N ₃ O	372.25	335–340 dec.	34	C ₂₀ H ₁₈ N ₂ O ₃	334.37	280–282
18	C ₁₉ H ₁₅ Cl ₂ N ₃ O	372.25	200–204 dec.	36	C ₂₀ H ₁₆ N ₂ O ₄	348.35	175–180
19	C ₁₉ H ₁₆ ClN ₃ O ₂	353.80	345–350 dec.	37	C ₁₈ H ₁₄ N ₂ O ₄	322.32	340–345
20	C ₂₀ H ₁₈ ClN ₃ O ₂	367.83	180–185 dec.				

TABLE 2

Nine subpanels at five concentrations: growth inhibition, cytostatic and cytotoxic activity (μM) of the selected compounds (see Supporting Information for the complete list of cell lines employed).

Comp ^a	Modes	Leukemia	NSCLC	Colon	CNS	Melanoma	Ovarian	Renal	Prostate	Breast	MG-MID ^b
4	GI ₅₀	1.62	3.02	1.95	1.58	2.14	2.00	2.45	2.24	2.14	2.14
	TGI	6.17	14.13	6.76	8.91	9.55	8.13	10.96	7.94	10.47	9.33
	LC ₅₀	37.15	53.70	23.44	35.48	41.69	38.90	37.15	30.90	50.12	39.81
7 ^c	GI ₅₀	0.14	0.43	0.17	0.12	0.23	0.28	0.23	0.22	0.15	0.21
	TGI	4.79	11.48	3.55	4.37	11.48	14.79	7.08	5.25	2.63	6.61
	LC ₅₀	58.88	52.48	25.70	41.69	35.48	48.98	46.77	41.69	39.81	41.69
8 ^c	GI ₅₀	18.20	34.67	22.91	26.92	15.14	30.20	41.69	22.39	18.62	23.99
	TGI	60.26	97.72	87.10	87.10	45.71	91.20	-	97.72	77.62	77.62
	LC ₅₀	97.72	-	-	-	57.54	-	-	-	95.50	91.20
9 ^c	GI ₅₀	2.51	1.91	1.55	0.93	1.55	3.47	1.70	1.55	0.95	1.66
	TGI	20.89	9.33	6.03	7.08	7.41	13.49	6.76	8.91	4.90	8.32
	LC ₅₀	-	37.15	29.51	38.90	31.62	43.65	26.92	26.30	31.62	36.31
10	GI ₅₀	10.00	18.20	12.30	10.72	10.23	10.47	11.22	20.42	6.92	11.22
	TGI	44.67	91.20	70.79	60.26	67.61	77.62	69.18	97.72	54.95	67.61
	LC ₅₀	87.10	-	-	-	93.33	91.20	-	-	-	97.72
12 ^c	GI ₅₀	0.02	0.07	0.02	0.02	0.02	0.03	0.04	0.02	0.05	0.03
	TGI	1.74	11.48	0.95	1.20	7.08	2.34	15.85	3.02	5.62	3.80
	LC ₅₀	39.81	93.33	25.12	23.44	50.12	52.48	70.79	21.38	72.44	48.98
13 ^c	GI ₅₀	0.25	0.58	0.20	0.20	0.34	0.38	0.33	0.39	0.28	0.32
	TGI	4.07	33.11	8.51	4.47	14.13	18.20	10.23	10.00	13.18	11.48
	LC ₅₀	46.77	-	72.44	74.13	69.18	95.50	79.43	66.07	95.50	77.62
14 ^c	GI ₅₀	0.05	0.22	0.07	0.04	0.11	0.26	0.11	0.10	0.06	0.10
	TGI	0.47	6.03	3.55	1.74	7.41	11.75	4.27	3.16	1.70	3.39
	LC ₅₀	19.95	42.66	26.92	29.51	33.11	47.86	36.31	23.99	40.74	33.88
15	GI ₅₀	6.92	19.50	20.42	10.47	16.22	18.62	15.85	35.48	6.76	14.13

Comp ^a	Modes	Leukemia	NSCLC	Colon	CNS	Melanoma	Ovarian	Renal	Prostate	Breast	MG-MID ^b
16^c	TGI	56.23	69.18	83.18	26.92	67.61	60.26	41.69	67.61	36.31	52.48
	LC ₅₀	-	93.33	97.72	61.66	-	89.13	77.62	-	83.18	87.10
	GI ₅₀	0.26	0.58	0.37	0.32	0.71	0.60	0.62	0.32	0.30	0.45
18^c	TGI	7.41	12.30	9.33	7.59	18.20	11.75	12.88	21.38	8.32	10.96
	LC ₅₀	69.18	57.54	46.77	47.86	51.29	61.66	56.23	69.18	57.54	56.23
	GI ₅₀	1.62	2.57	2.09	1.58	2.69	3.31	1.78	2.45	1.32	2.09
19	TGI	17.78	10.00	7.24	5.50	11.22	11.75	8.13	13.49	9.12	9.77
	LC ₅₀	91.20	46.77	22.91	18.20	37.15	41.69	29.51	46.77	54.95	38.90
	GI ₅₀	2.24	5.13	3.89	3.80	5.25	7.24	5.13	8.91	2.88	4.37
20^c	TGI	13.49	31.62	20.42	36.31	25.70	52.48	33.88	53.70	33.88	29.51
	LC ₅₀	-	95.50	69.18	-	79.43	-	91.20	-	-	91.20
	GI ₅₀	1.62	3.02	1.55	2.09	3.55	3.39	3.02	2.88	1.15	2.29
21	TGI	10.23	15.49	9.55	7.94	15.49	15.14	13.80	19.05	8.51	12.02
	LC ₅₀	72.44	58.88	30.20	32.36	44.67	50.12	52.48	50.12	54.95	48.98
	GI ₅₀	16.60	6.61	4.90	6.03	4.57	8.32	4.37	12.88	3.80	6.03
23^c	TGI	-	46.77	20.89	33.88	26.30	54.95	31.62	-	30.90	38.02
	LC ₅₀	-	85.11	61.66	85.11	66.07	95.50	87.10	-	-	83.18
	GI ₅₀	5.50	9.55	4.90	3.63	4.57	2.51	8.91	10.23	5.01	5.50
24^c	TGI	25.70	28.18	17.38	17.78	19.05	13.18	23.44	31.62	19.95	20.89
	LC ₅₀	75.86	72.44	47.86	53.70	46.77	57.54	56.23	63.10	67.61	58.88
	GI ₅₀	0.19	0.87	0.49	0.36	0.66	0.59	0.55	0.38	0.38	0.49
25^c	TGI	7.24	12.59	6.17	5.37	11.22	11.22	8.51	8.91	5.62	8.32
	LC ₅₀	72.44	58.88	35.48	47.86	40.74	61.66	52.48	38.02	54.95	51.29
	GI ₅₀	0.49	0.65	0.35	0.40	0.56	0.33	0.63	0.39	0.40	0.47
26	TGI	8.71	12.59	6.92	6.46	10.96	7.41	10.96	9.77	6.76	8.91
	LC ₅₀	87.10	70.79	57.54	51.29	44.67	41.69	43.65	51.29	70.79	56.23
	GI ₅₀	3.31	7.94	6.61	8.71	6.46	9.12	8.71	5.37	3.72	6.31
	TGI	38.02	30.20	20.89	24.55	20.89	46.77	33.11	26.30	19.05	26.92

Comp ^a	Modes	Leukemia	NSCLC	Colon	CNS	Melanoma	Ovarian	Renal	Prostate	Breast	MG-MID ^b
27 ^c	LC ₅₀	-	81.28	61.66	67.61	57.54	87.10	75.86	74.13	69.18	72.44
	GI ₅₀	0.19	0.63	0.31	0.31	0.56	0.40	0.49	0.25	0.23	0.37
	TGI	1.00	9.33	2.88	3.39	7.94	7.24	8.13	3.02	4.37	4.79
28 ^c	LC ₅₀	19.05	47.86	18.62	30.90	32.36	33.88	35.48	25.70	47.86	30.90
	GI ₅₀	0.01	0.06	0.02	0.02	0.03	0.04	0.04	0.01	0.02	0.03
	TGI	0.08	4.07	0.71	1.95	4.68	4.68	5.62	0.68	1.32	1.78
29	LC ₅₀	5.75	32.36	9.12	22.39	27.54	27.54	51.29	16.22	66.07	23.99
	GI ₅₀	2.34	5.13	2.24	6.17	6.61	6.31	5.75	5.62	3.47	4.57
	TGI	7.76	25.12	15.49	28.84	27.54	30.20	26.30	23.99	18.20	21.38
30 ^c	LC ₅₀	43.65	77.62	70.79	75.86	75.86	81.28	83.18	83.18	91.20	74.13
	GI ₅₀	0.09	0.11	0.09	0.15	0.12	0.18	0.23	0.07	0.12	0.13
	TGI	2.88	16.98	3.98	3.63	7.41	7.76	6.92	12.88	6.76	6.46
32	LC ₅₀	64.57	77.62	22.91	53.70	50.12	58.88	53.70	63.10	75.86	54.95
	GI ₅₀	8.71	13.49	8.13	10.00	13.18	12.59	11.48	13.80	11.75	11.22
	TGI	54.95	43.65	52.48	33.88	37.15	45.71	38.02	36.31	40.74	42.66
33 ^c	LC ₅₀	-	89.13	95.50	95.50	81.28	97.72	85.11	91.20	91.20	91.20
	GI ₅₀	2.00	6.31	0.76	1.07	3.09	7.76	4.17	4.17	1.78	2.75
	TGI	35.48	66.07	60.26	42.66	74.13	60.26	60.26	81.28	54.95	57.54
34	LC ₅₀	93.33	93.33	97.72	95.50	97.72	-	-	-	-	97.72
	GI ₅₀	3.47	6.03	2.95	3.72	3.24	5.62	5.89	3.55	2.75	4.07
	TGI	36.31	21.88	24.55	23.99	15.14	31.62	28.18	15.85	16.22	22.91
Vincristine sulfate ^d	LC ₅₀	-	91.20	-	67.61	66.07	95.50	93.33	-	63.10	83.18
	GI ₅₀	0.10	0.25	0.10	0.13	0.16	0.32	0.32	0.13	0.32	0.20
	TGI	15.85	15.85	3.98	6.31	7.94	19.95	19.95	6.31	7.94	10.00
	LC ₅₀	630.96	251.19	79.43	199.53	251.19	316.23	251.19	316.23	316.23	251.19

^a Highest conc. = 10⁻⁴M unless otherwise reported; only value > 100 μM are reported. The compound exposure time was 48 hours

^b Mean Graph MIDpoint i.e. the calculated panel mean

^c Mean of two separate experiments

^d Highest conc. = 10^{-3} M